07:00 , May 16, 2016 |  BC Week In Review  |  Clinical News

Brincidofovir: Phase III data

Next half, Chimerix plans to disclose final 36-week mortality data from AdVise. The company will not seek brincidofovir’s approval based on the AdVise data and instead intends to conduct a comparative trial. Chimerix said it...
01:25 , May 10, 2016 |  BC Extra  |  Clinical News

Brincidofovir fails to improve survival in adenovirus study

Chimerix Inc. (NASDAQ:CMRX) slipped $0.21 to $4.91 on Monday after disclosing with its 1Q16 financial results that brincidofovir ( CMX001 ) did not meaningfully improve overall survival at week 24 compared to historical controls in...
08:00 , Feb 29, 2016 |  BC Week In Review  |  Clinical News

Brincidofovir: Additional Phase III data

Additional data from the double-blind, international Phase III SUPPRESS trial in 452 CMV-seropositive hematopoietic stem cell transplant (HSCT) recipients showed that 51% of patients who received twice-weekly 100 mg oral brincidofovir had clinically significant CMV...
02:39 , Feb 23, 2016 |  BC Extra  |  Clinical News

Chimerix falls after brincidofovir update

Chimerix Inc. (NASDAQ:CMRX) fell $3.08 (40%) to $4.55 on Monday after reporting detailed data over the weekend from the Phase III SUPPRESS trial of brincidofovir ( CMX001 ) to prevent cytomegalovirus (CMV) infections and discontinuing...
08:00 , Jan 4, 2016 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 12/31 cls ArQule Inc. (NASDAQ:ARQL) RBC Capital Markets Adnan Butt Upgrade Outperform (from sector performer) -3% $2.17 Butt also raised...
08:00 , Jan 4, 2016 |  BioCentury  |  Product Development

Turnabout

The firestorm over compassionate access that pushed Chimerix Inc. into studying brincidofovir in adenovirus last year already saved the life of Josh Hardy and may now prove to be the company's saving grace as well....
08:00 , Jan 4, 2016 |  BC Week In Review  |  Clinical News

Brincidofovir: Phase III data

Top-line data from the double-blind, international Phase III SUPPRESS trial in 452 CMV-seropositive hematopoietic stem cell transplant (HSCT) recipients showed that 100 mg oral brincidofovir twice weekly missed the primary endpoint of a lower incidence...
01:48 , Dec 29, 2015 |  BC Extra  |  Top Story

Chimerix crushed on Phase III brincidofovir miss

Chimerix Inc. (NASDAQ:CMRX) dropped $28.95 (81%) to $6.62 on Monday after brincidofovir ( CMX001 ) missed its primary endpoint in the Phase III SUPPRESS trial. The candidate failed to prevent clinically significant cytomegalovirus (CMV) infection...
08:00 , Nov 2, 2015 |  BC Week In Review  |  Clinical News

Brincidofovir: Phase III started

Chimerix began the double-blind, active-controlled, Phase III SURPASS trial to compare twice-weekly 100 mg brincidofovir vs. valganciclovir for up to 14 weeks post-transplant in about 520 kidney transplant recipients who are CMV seropositive pre-transplant and...
08:00 , Nov 2, 2015 |  BC Week In Review  |  Clinical News

Brincidofovir: Phase III started

Chimerix began the double-blind, active-controlled, international Phase III SUSTAIN trial to compare twice-weekly 100 mg brincidofovir vs. valganciclovir for up to 28 weeks post-transplant in about 750 patients who are CMV seronegative pre-transplant and received...